Plus Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY Revenue (est.)
$6.3Mnext fiscal year
FY EPS (est.)
-$3.92next fiscal year
Monitoring Framework
Key Performance Indicators
CNSide Covered Lives Quarterly81M
CNSide Annualized Test Orders Annually
Cash and Investments Balance Quarterly15.1MTarget: Maintain sufficient runway through mid-2027
Watch Items
- ReSPECT-LM Phase 2 Trial Dose OptimizationTrigger: Reporting of optimal dose/interval data in Q3 2026Action: Evaluate efficacy and safety endpoints to finalize pivotal trial design with the FDA
- ReSPECT-GBM Phase 2 Trial EnrollmentTrigger: Full enrollment of Phase 2 trial by the end of 2026Action: Prepare for End of Phase 2 meeting with the FDA to align on pivotal trial design
- Manufacturing Scale-Up for REYOBIQTrigger: Completion of technology transfer and clinical supply readiness with SpectronRx in 2026Action: Ensure GMP-compliant clinical supply availability for upcoming pivotal trials
Research as of 19 Jun 2026